Biosimilar antibodies and cell

Recombinant Human Biosimilars (RUO)

Leinco Technologies is a leader in developing and manufacturing recombinant antibodies for early discovery research and diagnostics. Leinco’s extensive line of recombinant biosimilars follow stringent product specifications and undergo IMPACT testing.

Therapeutic antibodies are widely used for the treatment of diseases, including cancer and autoimmunity. However, therapeutic-grade biologics are expensive, challenging to source, and only available in large quantities, making studies using these antibodies cost prohibited. Research-grade biosimilar antibodies are produced by recombinant technology using the variable region sequences of therapeutic antibodies, resulting in the same specificities as approved biologics. Leinco’s recombinant biosimilar antibodies are ideal research tools as they are fast, inexpensive, manufactured in an animal free facility and formulated in sterile PBS buffer, free of additives or preservatives.

Leinco Technologies offers high-purity research-grade biosimilar antibodies with the same specifications as the following therapeutic antibodies: Trastuzumab, Efalizumab, Mogamulizumab, Rituximab, Tabalumab, Nivolumab, Natalizumab, Alemtuzumab, Ipilimumab, Drozitumab, Cetuximab, Briakinumab, Basiliximab, Sarilumab, Oxelumab, Adalimumab, and Bevacizumab. All antibodies are available with Fc Active or Fc Mutedeffector functions.

Research Use Only Biosimilar Offerings

*These products are for research use only and should not be used for any therapeutic purposes.

Biosimilar Antibodies Therapeutic Use Product Number
Anti-Human TNF alpha (Adalimumab)
To reduce inflammation of the joints, skin, spine, gut, and eyes.* Active LT100
Muted™ LT105
View All Conjugates
Anti-Human CD52 (Alemtuzumab)
To treat chronic lymphocytic leukemia (CLL) and multiple sclerosis.* Active LT200
Muted™ LT205

View All Conjugates
Anti-Human IL-2R alpha (Basiliximab)
To prevent rejection in organ transplantation, especially in kidney transplants.* Active LT300
Muted™ LT305
View All Conjugates
Anti-Human VEGF (Bevacizumab)
To treat colon cancer, lung cancer, glioblastoma, renal-cell carcinoma, and some eye diseases.* Active LT400
Muted™ Lt405
View All Conjugates
Anti-Human IL 12/23 (Briakinumab)
To treat rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.* Active LT500
Muted™ LT505
View All Conjugates
Anti-Human EGFR (Cetuximab)
To treat metastatic colorectal cancer and head and neck cancer.* Active LT600
Muted™ LT605
View All Conjugates
Anti-Human DR5 (Drozitumab)
To treat various types of cancers.* Active LT700
Muted™ LT705
View All Conjugates
Anti-Human CD20 (Rituximab)
To treat non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers.* Active LT800
Muted™ LT805
View All Conjugates
Anti-Human CD11a (Efalizumab)
To treat auto-immune diseases and psoriasis* Active LT900
Muted™ LT905
View All Conjugates
Anti-Human CD194  (Mogamulizumab)
To treat relapsed or refractory mycosis fungoides and Sézary disease.* Active LT1000
Muted™ LT1005
View All Conjugates
Anti-Human CD49D (Natalizumab)
To treat multiple sclerosis and Crohn’s disease.* Active LT1100
Muted™ LT1105
View All Conjugates
Anti-Human PD-1 (Nivolumab)
To treat melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, and gastric cancer.* Active LT1200
Muted™ LT1205
View All Conjugates
Anti-Human OX40L (Oxelumab)
To treat asthma.* Active LT1300
Muted™ LT1305
View All Conjugates
Anti-Human CD257  (Tabalumab)  To treat autoimmune diseases and B cell malignancies.* Active LT1400
Muted™ LT1405
View All Conjugates
Anti-Human HER-2  (Trastuzumab)
To treat breast cancer and stomach cancer.* Active LT1500
Muted™ LT1505
View All Conjugates
Anti-Human CTLA-4 (Ipilimumab)
To treat late stage melanoma.* Active LT1600
Muted™ LT1605
View All Conjugates
Anti-Human IL-6 (Sarilumab)
To treat moderately to severely active rheumatoid arthritis.* Active LT1700
Muted™ LT1705
View All Conjugates

Custom Biosimilar Production

Don’t see the biosimilar you are looking for? Just send us the sequence, and we can custom make any biosimilar of your choice.

View Services
Shop All Biosimilar Antibodies